Mylan N.V. (MYL) News

Mylan N.V. (MYL): $15.85

0.30 (+1.96%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter MYL News Items

MYL News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest MYL News From Around the Web

Below are the latest news stories about Mylan NV that investors may wish to consider to help them evaluate MYL as an investment opportunity.

Global Reversible Airway Diseases Treatment Market 2020: Covering Competitive Scenario And Dynamics By Mylan N.V., Boehringer Ingelheim International GmbH, Regeneron, Sanofi, Genentech, Inc. (F. HoffmannLa Roche Ltd), Novartis AG

Data Bridge Market Research has provides the Qualitative and informative knowledge by adding titled “Global Reversible Airway Diseases Treatment Market, By Type (Bronchodilators, Cytotoxic Drugs, Antibiotics, Others), Treatment (Chest X Ray, CT Scan, Lung Therapies, Surgery Transplant and Medications), Diseases

OpenPR | October 1, 2020

Carboplatin Market In-Depth Analysis Of Competitive Landscape, Executive Summary, Development Factors 2026(Fresenius Kabi, Mylan, Qilu)

Los Angeles, United State, – – QY Research recently added a research report, Global Carboplatin Market Research Report 2020 to its ever-increasing repository. The research report discusses the future of the global Carboplatin market. It highlights the drivers and restraints

OpenPR | September 30, 2020

Drug Addiction Treatment Market Strategic Insights 2020 with analysis of Leading Players: Pfizer, Indivior, Novartis, Alkermes, Cipla, Mylan, Dr. Reddy's Laboratorie, etc.

The Global Drug Addiction Treatment Market research study takes a comprehensive approach towards studying the key trends influencing the growth of this sector. The report comprises data that offers an in-depth insight into the business sector. The research report focuses

OpenPR | September 30, 2020

Outstanding Growth of Opioids Drug Market is estimated to reach $11.8 Billion by 2025 | International Company’s - J&J, Teva, Mylan, Pfizer, Mallinckrodt

Global Opioids Drug Market Synopsis: The Opioids Drug Market has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Opioids Drug Market size to maintain the average annual growth rate of 0.83% from $11.1

OpenPR | September 29, 2020

Calcium Folinate Market 2020: Growing Demand for Efficient Management Observes Report Till 2025 with Merck, Teva, Mylan

The Calcium Folinate market 2020 research report is a detailed view of market opportunity by end-user segments, product Type segments, sales channels, key countries. It also provides market credentials such as history, various development and trends, market overview, regional

OpenPR | September 28, 2020

Uzbekistan and specific city Tashkent And Global Hydroxychloroquine for COVID-19 Market Size is Thriving Worldwide with Topmost Companies Like:Sanofi, Novartis, Shanghai Zhongxisanwei, Teva, Zydus Cadila, Mylan, Apotex

Los Angeles, United State, – – QY Research recently added a research report, Global Hydroxychloroquine for COVID-19 Market Research Report 2020 to its ever-increasing repository. The research report discusses the future of the global Hydroxychloroquine for COVID-19 market. It highlights

OpenPR | September 28, 2020

Rituximab Biosimilars Market Is Booming Worldwide (2020-2023) | By Top Leading Players – Pfizer Inc., Mylan Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd.

The Business Research Company offers "Rituximab Biosimilars Global Market Report 2020-30: COVID-19 Growth And Change" in its research report store. It is the most comprehensive report available on this market and will help gain a truly global perspective as it

OpenPR | September 28, 2020

Mylan and Pfizer Receive European Commission Approval for Proposed Combination of Mylan and Upjohn

HERTFORDSHIRE, England, PITTSBURGH and NEW YORK, Sept. 15, 2020 /PRNewswire/ -- Mylan (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the companies have received final approval from the European Commission (EC) for the proposed combination of Mylan and Pfizer Inc.'s Upjohn…

PR Newswire | September 15, 2020

Blueprint Receives FDA Approval, And Other News: The Good, Bad And Ugly Of Biopharma

FDA approves Blueprint’s GAVRETO for lung cancer Blueprint Medicines Corporation (BPMC) announced that the FDA has given its approval to GAVRETO for treating adult patients with metastatic rearranged during transfection fusion-positive non-small cell lung cancer. Blueprint is collaborating with Roche (RHHBY), and the drug will be commercialized in the United...

Avisol Capital Partners on Seeking Alpha | September 10, 2020

Mylan to Present at the BofA Securities Virtual Global Healthcare Conference

HERTFORDSHIRE, England and PITTSBURGH, Sept. 9, 2020 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that Executive Chairman Robert J. Coury, together with President Rajiv Malik will present at the BofA Securities Virtual Global Healthcare Conference…

PR Newswire | September 9, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7168 seconds.